Business
Kyverna Therapeutics and National Institutes of Health Co-Author Seminal Review on Cell Therapy for Autoimmunity in Nature Reviews Immunology
Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseases Optimal CAR construct design contributing to
About this update from Kyverna Therapeutics, Inc.
[{"type":"text","content":"Promising results from early clinical experience with anti-CD19 CAR T cells in patients with autoimmune diseases\nOptimal CAR construct design contributing to an acceptable safety profile, and potential for lasting immune reset are key for treatment adoption \nKyverna is currently recruiting for multiple KYSA trials where the company's product candidate KYV-101 is used to treat patients suffering from myasthenia gravis, multiple sclerosis, and lupus nephritis\nEMERYVILLE, Calif., June 10, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the publication in Nature Reviews Immunology of a manuscript co-authored with the National Institutes of Health titled \"Chimeric antigen receptor T cell therapy for autoimmune disease\"1.\n\n \n \n \n \n \n \n\n \nWith more than 30 ongoing sponsored clinical trials and a growing number of published clinical evidence suggesting the potential of CAR T-cell therapy approaches for autoimmune diseases, the manuscript highlights key considerations on optimal target cell population, CAR construct design, acceptable toxicities, and potential for lasting immune reset.\n\"It is quite exciting to see how the learnings from the development of innovative CAR T-cell approaches for the treatment of cancer patients are now being applied to the treatment of patients with autoimmune diseases,\" said James Kochenderfer, M.D., senior investigator, clinician, and translational researcher in the Surgery Branch of the National Cancer Institute, National Health Institutes of Health in Bethesda, MD. \"I look forward to seeing further progress in this emerging field ultimately leading towards a potential breakthrough in patient treatment.\"\n\"We are very proud of our scientific collaboration with widely recognized opinion leaders in CAR T-cell therapy,\" said Peter Maag, Ph.D., chief executive officer of Kyverna. \"By rapidly advancing an evidence-based science we may bring potentially long-lasting, treatment-free therapeutic options to many patients in need.\"\nAbout KYV-101KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes o...